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Abstract
Background: Early differential diagnosis between acute bacterial and viral meningitis is problematic. We aimed to
investigate whether the detection of lipocalin 2, a protein of the acute innate immunity response, may be used as a
marker for acute bacterial meningitis.
Methods: Transgenic mice expressing the human transferrin were infected by intraperitoneal route and were
imaged. Cerebrospinal fluid (CSF) was sampled up to 48hours post- infection to measure lipocalin 2. We also tested
a collection of 90 and 44 human CSF with confirmed acute bacterial or acute viral meningitis respectively.
Results: Lipocalin 2 was detected after 5 h in CSF during experimental infection in mice. Lipocalin 2 levels were
significantly higher (p < 0.0001) in patients with confirmed acute bacterial meningitis (mean 125 pg/mL, range
106–145 pg/mL) than in patients with acute viral meningitis (mean 2 pg/mL, range 0–6 pg/mL) with a sensitivity of
81%, a specificity of 93%, a positive predictive value of 96% and a negative predictive value of 71% in diagnosing
acute bacterial meningitis.
Conclusions: Increased levels of lipocalin 2 in cerebrospinal fluid may discriminate between acute bacterial and
viral meningitis in patients with clinical syndrome of meningitis.
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Background
Acute bacterial meningitis (ABM) is a major cause of
morbidity and mortality worldwide. The Wold Health
Organization (WHO) estimates that there are around
1 million of cases per year worldwide with 135–200,000
fatal cases [1]. Haemophilus influenzae type b (Hib),
Streptococcus pneumoniae (Sp), and Neisseria meningi-
tidis (Nm) are the most frequent agents of ABM. Other
agents are also incriminated in infants such as Strepto-
coccus agalactiae and Escherichia coli K1. ABM is a
medical emergency and requires immediate management
that relies mainly on appropriate and prompt antibiotic
treatment. However, the major differential diagnosis of
ABM is acute viral meningitis (AVM) that does not
require antibiotics and are usually of better prognosis.
Laboratory confirmation requires lumber puncture and
analysis of the cerebrospinal fluid (CSF). Etiologic diag-
nosis of ABM is performed by culture and non-culture
methods (smear detection, nucleic acid detection by
PCR and/or antigen detection by agglutination kits) [2].
Recognition of ABM is therefore needed at the admission
and accurate diagnosis is mainly based on examination
of CSF. Pleocytosis with predominance of polymorpho-
nuclear leukocytes (PMN), low level of glucose in CSF
with low CSF-blood glucose ratio and increase in CSF pro-
tein levels are usually encountered in ABM. However,
overlapping values between ABM and AVM are reported.
While 71% of patients with ABM may have a leukocyte
count of ≥1000 cells/μl in CSF samples, 15% of patients
with AVM may display similar counts in CSF and up to
10% of ABM cases may show leukocyte counts of <100
cells/μl [3,4]. Cut-off values differed among studies with
variable performances [5]. Analysis of CSF in meningitis
may allow discriminating ABM from AVM and guide the
decision to administer (or not) antibiotics [6,7]. Scores
were developed for this purpose combining both clinical
signs and biological markers such as serum levels of
C-reactive protein (CRP) and procalcitonin (PCT) [4,8,9].
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The lipocalin 2 (LCN2) is a small protein of 22 kDa
involved in iron homeostasis that allows an alternative
method to transferrin to deliver iron to the cytoplasm
[10]. LCN2 was initially discovered in the granules of
the polymorphonuclear cells and was called Neutrophil
Gelatinase Associated Lipocalin (NGAL) [11]. LCN2 is a
part of the acute innate immune response to bacterial
infection. It allows sequestrating iron through interfering
with siderophore-mediated iron acquisition by bacteria
[12,13]. We have recently reported transcriptomic analysis
in an experimental sepsis in transgenic mice expressing
the human transferrin [14]. Several differentially expressed
transcripts (DETs) corresponding to acute phase proteins
were detected. Interestingly, one of these proteins, LCN2,
was overexpressed in the brain of infected mice after 6 h
of infection. LCN2 was also reported as an acute phase
protein to be produced at the blood brain barrier by the
choroid plexus epithelial cells and the endothelial cells of
blood vessels [15]. We aimed to explore the detection of
LCN2 in CSF as a marker of acute bacterial meningitis.
Methods
Clinical samples and patients
One hundred thirty four cerebrospinal fluids (CSF)
addressed to the National Reference Center for Menin-
gococci (NRCM) for molecular diagnosis of bacterial
meningitis were tested. Available epidemiological data
(age, sex), clinical and biological data, C-reactive pro-
tein (CRP) in blood, CSF levels of protein and glucose
were analyzed. Confirmed ABM was defined as more than
100 leukocytes in CSF and the detection of bacteria
(culture, PCR, slide agglutination or positive smear
detection). PCR-based diagnosis was performed as pre-
viously described [16]. Enterovirus PCR was performed
in hospitals that sent CSF samples to the NRCM.
Generation of the bioluminescent LNP24198lux strain
N. meningitidis strain LNP24198 is a clinical isolate of
serogroup C, serotype 2a and serosubtype P1.7,1 (PorA
VR1 = 7-1 and VR2 = 1) that belongs to the clonal com-
plex ST-11 [17]. The plasmid pXen-13 containing Photo-
rhabdus luminescence luxCDABE operon was purchased
from Xenogen Corp., Alameda, CA and was modified
by insertion of a Neisseria specific promoter sequence.
A 600 bp promoter sequence of the meningococcal porB
gene (PporB) was PCR amplified using primers PorB3
(5′-GGTGCTGAAGCACCAAGTGA -3′) and PorB4
(5′- GGCAATCAGGGATTTTTTCA-3′) and subcloned
into a BamHI site upstream of the luxCDABE operon to
express the luxCDABE operon under the control of the
PporB meningococcal promoter N. meningitidis. The
generated plasmid was named pDG33. The fragment
encompassing the luxCDABE cassette and the porB
promoter was extracted by digesting pDG33 with KpnI
and SacI restriction enzymes and inserted into BamHI
site of the plasmid pTE-KM [18], upstream the kanamy-
cin aph3’ resistance cassette. The resulting vector was
named pDG34 in which, the PporB-luxCDABE-aph3’
was flanked by the meningococcal pilE gene and 120 bp
downstream pilE gene to facilitate the recombination
upon transformation to obtain the LNP24198lux strain.
Animal infection, analysis and imaging studies
We have previously described the use of transgenic mice
expressing the human transferrin infected by intraperito-
neal route (ip) as an experimental model of meningococ-
cal infection [19]. Mice were in-house bred and were
kept in a biosafety containment facility, in filter-topped
cages with sterile litter, water and food, according to in-
stitutional guidelines.
Each mouse was infected with standardized inocula of
the bioluminescent strain LNP 24198lux. Bacterial infec-
tion images were acquired using an IVIS® 100 system
(Xenogen Corp., Alameda, CA) according to instructions
from the manufacturer and as previously described [14].
Analysis and acquisition were performed using Living
Image® 3.2 software (Xenogen Corp.). Images were ac-
quired using 1 min of integration time with a binning of
16. All other parameters were held constant. Quantifica-
tion was performed using the total photons per second
emitted by each mouse after 30 min, 2 h, 5 h and 24 h
of infection by defining regions of interest. An unin-
fected mouse under the same conditions of acquisition
was used to define the background. After each imaging
point, CSF samples (10 μl) were collected in a 30 μl 0.9%
NaCl from each mouse by puncture from the cisterna
magna as previously described [20]. Serial dilutions of CSF
samples were plated on GCB medium supplemented with
Kellogg supplements to determine the number of colony
forming units (CFU).
Ethics statement
This study was carried out in strict accordance with the
European Union Directive 2010/63/EU (and its revision
86/609/EEC) on the protection of animals used for sci-
entific purposes. Our laboratory has the administrative
authorization for animal experimentation (Permit Number
75–1554) and the protocol was approved by the Institut
Pasteur Review Board that is part of in the Regional Com-
mittee of Ethics of Animal Experiments of Paris region
(Permit Number: 99–174). CSF samples were initially
received for diagnosis that is part of the primary man-
agement of suspected meningococcal meningitis. The
patients were informed on the secondary use of CSF
samples for research and they gave their consent for this
use. The printed form of this informed consent is sent
to our laboratory. This procedure is performed accord-
ing to the French public health code (Art L1211-2).
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Western blot and Enzyme-linked immunosorbent assay
(ELISA)
Thirty micro liters of human CSF, 15 μl of diluted CSF
(see above) or 2 μl of blood from infected mice were
separated in 14% SDS- polyacrylamide gels and then
transferred onto nitrocellulose membrane. Western blot-
ting was performed as previously described [21] using
anti-human or anti-mouse lipocalin 2 antibody (Abcam,
Cammbridge, UK). Densitometry was performed using
Image J® software (http://imagej.nih.gov/ij/). All density
data were corrected for the background by subtraction
of the density of the negative control (confirmed non
bacterial meningitis). Results were then expressed as a
ratio of the corrected density obtained for each CSF over
the corrected density obtained for the positive control
(confirmed acute bacterial meningitis). ELISA was per-
formed with lipocalin2/NGAL Human ELISA kit® (Abcam,
Cambridge, UK) according to the manufacturer’s recom-
mendations. The expression of LCN2 gene in mice was
performed by reverse-transcriptase-PCR (RT-PCR) ana-
lysis as previously described [22].
Statistical analysis
Qualitative data were analyzed using the Chi-square test.
Statistically significant differences were assumed when p
< 0.05. Geometric means as well as lower and upper 95%
confidence intervals were calculated using GraphPad
InStat® version 3.06 (GraphPad Software, San Diego, CA,
USA). Specificity, sensitivity, positive predictive value,
negative predictive value and likelihood ratios were cal-
culated as previously described [23].
Results
Analysis of lipocalin 2 expression during experimental
meningococcal infection
We first explored whether lipocalin 2 was detectable in
CSF from infected mice during experimental infection as
expected from the previously reported overexpression of
lipocalin 2 specific transcripts in brain [14]. Two groups
of 7 and 8 BALB/c female mice were infected intraperi-
toneally by 106 CFU/mice or 107 CFU/mice of the strain
LNP24198lux respectively and 3 uninfected mice were
used as controls. Mice were imaged at 30 min, 2 h, 5 h
and 24 h (Figure 1A). Two or three mice from each bac-
terial dose were anesthetized at 2 h, 5 h and 24 h of in-
fection and CSF samples were withdrawn (see Material
and Methods). Bacterial counts in CSF were determined
by serial plating (Figure 1B) and lipocalin 2 was detected
in CSF samples by Western blotting (Figure 1C). Bio-
luminescent signals remained localized at the injection
site 30 minutes after the bacterial infection but spread
rapidly after 2 hours particularly in mice that received
the highest bacterial dose. The total emitted photons on
the skulls increased and paralleled the increase in the
bacterial counts in CSF and in blood (Figure 1B and data
not shown). In CSF, bacteria were detected at 2 h of in-
fection and lipocalin 2 was detected at 5 h of infection
in mice that received the highest bacterial dose and at
24 h for both doses of infection. At these points, very
few leukocytes were detected in CSF of infected mice
(data not shown). The detection of lipocalin 2 in blood
also matched that in CSF (Figure 1).
The experiment was repeated using the 107 CFU/mice
dose and CSF samples were taken up to 72 hours of infec-
tion. Lipocalin 2 was again detectable at 5 h after infection,
reached a peak at 24 h then decrease and was no more de-
tectable at 72 h (Figure 1C and data not shown).
RT-PCR performed on RNA extracted from the brain
of infected and non-infected mice confirmed the induc-
tion of the gene encoding the lipocalin 2 as previously
described [14]. This induction was also observed in
blood (data not shown). All these results confirm the in-
duction and the early detection of lipocalin 2 in the CSF
after bacterial infection in mice.
Characterization and classification of human CSF from
clinical samples
We next aimed to test whether lipocalin 2 can be de-
tected in CSF from patients with acute bacterial menin-
gitis. We explored a large collection of CSF samples
(n = 134) that are received at the National Reference
Center for Meningococci for non-culture diagnosis by
PCR. The samples were classified in two groups: The
first group (group 1) included 90 CSF (67%) that showed
more than 100 leukocytes and were positive for at least
one of the following tests: PCR, culture, smear detection
or slide agglutination. N. meningitidis (Nm) was the
main bacterial agent that was detected in our samples
(n = 88) due to the fact that samples were tested for sus-
pected meningococcal meningitis. One sample was posi-
tive for S. pneumoniae (Sp) and another was positive for
Streptococcus group A. This group corresponded to con-
firmed bacterial meningitis. Nm positive samples were of
several groups; 73% NmB (n = 66), 12% NmC (n = 11),
7% NmW (n = 6), 6% NmY (n = 5). The multi locus
sequence typing (MLST), that determines the clonal
complex, was performed for 45 (51% of Nm positive
samples): 10 belonged to the hyperinvasive clonal com-
plex ST-11 and 35 belonged to other clonal complexes.
The second group (group 2) included 44 CSF that corre-
sponded to PCR-confirmed acute enteroviral meningitis.
The characteristics of patients and CSF of each of these
two groups are presented in Table 1. In spite of overlap-
ping values, biological markers of acute bacterial menin-
gitis differed significantly between group 1 and group 2.
In particular, known biological markers for ABM were
present such as high numbers of leucocytes (mean
7133), and high proportion of neutrophils (mean 87%),




Figure 1 (See legend on next page.)
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high protein levels (mean 3.4 g/L) and low levels of glu-
cose in CSF (mean 1.6 mmol/L) and CRP in blood
(mean 188 mg/L) (Table 1 and Figure 2).
Analysis of levels of lipocalin 2 in human CSF
We next tested all the 134 CSF samples from the two
groups by Western blotting using antibodies against hu-
man LCN2 and using an ELISA kit (Abcam, Cambridge,
UK). Western blotting showed the expected band with
an apparent molecular mass of 22 kDa that was ob-
served with variable intensities (Figure 3). Western blots
and ELISA were analysed as described in Material and
Methods section after normalization with the negative
and positive controls. Data from ELISA and Western
blotting showed significant variations (p < 0.0001) in the
levels of LCN2 that were detected in CSF among the
two groups of CSF. CSF from group 1 (acute bacterial
meningitis) showed higher levels of LCN2 than group 2
(acute viral meningitis) (Table 1). We also compared the
two groups for other biological markers of inflammation:
the blood level of CRP and CSF markers of acute bacter-
ial meningitis such as high levels of protein and low
levels of glucose. These comparisons also corroborated
the levels of LCN2 in CSF in group 1 (confirmed ABM)
compared to group 2 (confirmed AVM) (Table 1 and
Figure 2). As a biological marker of acute bacterial men-
ingitis, the detection of lipocalin 2 in CSF has a sensitiv-
ity of 81%, a specificity of 93%, a positive predictive
value of 96% and a negative predictive value of 71%. The
likelihood ratio of a positive test result is 11.6 (the
sensitivity divided by 1- specificity). The likelihood ratio
of a negative test result is 0.2 (1- sensitivity divided by
specificity).
All these data taken together, strongly suggest that
lipocalin 2 can be used as a marker to help confirming
acute bacterial meningitis.
Discussion
Reliable tests that allow early discrimination between
ABM and AVM are still lacking, and biological findings
in blood and CSF are quite similar and indecisive at the
onset of the disease. Indeed, 12 hours of illness may be
required before CRP to increase above normal levels in
ABM [24]. Moreover, CRP may also increase in acute
viral meningitis [4,25]. PCT also requires 6 hours to in-
crease in ABM [26]. Pleocytosis and neutrophil predom-
inance usually characterize ABM but they can be
observed in AVM and may be absent in about 10% of
ABM [27]. In a retrospective study, leukocyte counts in
viral meningitis ranged between 42 and 320 per mm3
with a mean of 110 per mm3 [28] compared to the mean
of 160 per mm3 in our study. These markers associated
with clinical signs and symptoms may be sensitive in
recognizing ABM but may still lack specificity and hence
do not allow avoiding unnecessary antibiotic treatment
[29]. Other markers were also tested to discriminate
AVM from ABM such as the soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1), haemoglobin
scavenger receptor (CD163) and High Mobility Group
Box 1 (HMGB1). As for CRP and PCT, these markers
Table 1 Characteristics of patients and CSF tested
Group 1 Group 2
Confirmed acute bacterial meningitis n = 90 Confirmed acute viral meningitis n = 44
Mean IC 95% Mean IC 95% p
Age, y 21 17-25 4.5 3-6 <0.0001
CSF cytology, mm3 7133 4625-9642 160 90-230 <0.0001
CSF PMN, % 87 83-91 46 35-57 <0.0001
CSF Protein, g/L 3.4 2.7-4.2 0.5 0.3-0.7 <0.0001
CSF glucose, mmol/L 1.6 1.3-2 3.3 3.2-3.5 <0.0001
Blood CRP, mg/L 188 157-219 14 9-18 <0.0001
CSF LCN2, pg/mL 127 108-146 2.4 0-6.2 <0.0001
(See figure on previous page.)
Figure 1 Dissemination of N. meningitidis in BALB/c mice that were infected by intraperitoneal injection of 106 CFU (low dose) or 107
CFU per mouse (high dose) of N. meningitidis strain LNP 24198lux expressing the luciferase. Mice were analyzed for bioluminescence at
the indicated times. Images depict photographs overlaid with colour representations of luminescence intensity, measured in photons/s-cm2-sr
and indicated on the scales, where red is most intense and blue is least intense. (Top row) (A) Dorsal views of 8 mice (high dose) and 7 mice
(low dose). A non infected mouse (NI) is also shown (B). The luminescence was quantified and expressed as means ± SD from each category at
the indicated times by defining specific representative region of interest encompassing the entire animal. (C) Western blotting of CSF and blood
from mice to detect lipocalin 2 (arrows) after the indicated time points of infection and using 106 CFU (low dose) or 107 CFU per mouse (high
dose) as in (A).
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are produced during the acute phase of inflammation in
response to release a large number of released bacterial
components such as lipopolysaccharide (LPS) and pep-
tidoglycan (PG) [30]. These markers may be of interest
to evaluate the severity of serious bacterial systemic
infections [31,32]. The concentrations of inflammatory
cytokines such as TNF-alpha, IL-1beta and IL-8 in the
CSF were also analysed in the differential diagnosis of
meningitis [33,34] but cannot be used in routine prac-
tice. Recently, heparin-binding protein (HBP) was also
suggested as a marker for acute bacterial meningitis as
HBP was shown to increase in CSF in patients with
ABM but the earliness of this increase was not evaluated
[35]. In spite of plethora of markers, the question of dis-
criminating AVM from ABM is still debated and how to
make the decision of rapid administration of broad-
spectrum antibiotics is still open.
Figure 2 Cerebrospinal fluid levels of LCN2, cytology, glucose, protein and blood CRP in the two groups. Median values and 95%
confidence intervals are given.
25kDa
22kDa
Group 1 Group 2Group 2
1        2           3         4         5          6
Figure 3 Western blotting on human CSF with anti-LCN2
antibody. Data are from individual CSF samples from groups 1 and 2.
Molecular markers are indicated on the left. Results of meningococcal
detection and the corresponding group of tested CSF are indicated.
Group 1 (confirmed acute bacterial meningitis) and Group 2 (confirmed
acute viral meningitis).
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LCN2 has a bacteriostatic effect as it is able to seques-
ter siderophores that are essential for bacterial survival
[12,13,36]. Lipocalin 2 knock-out mice succumbed rap-
idly after intraperitoneal infection of Escherichia coli, in
contrast to wild-type mice [12]. Lipocalin 2 is an acute
phase protein and an actor of the innate immunity [37].
It has multifaceted roles and is involved in several path-
ologies [38]. Our study in mice suggests that lipocalin 2
is not detectable in CSF of non infected mice and can be
detected as early as 5 h after infection and before the
pleocytosis. This may be due to the induction of the ex-
pression of LCN2 from epithelial cells of the choroid
plexus [15]. Our imaging data in mice are compatible
with this explanation as bioluminescent bacteria were
clearly located in the skull and bacteria were detected in
CSF. The highest levels of LCN2 were thereafter de-
tected at 24 h when pleocytosis may also amplify the
levels of LCN2 in CSF.
Variations in the level of LCN2 were observed among
patients with confirmed ABM. Early antibiotic treatment
(n = 38 in group 1 of our collection) and/or corticoste-
roids may modify LCN2 production. The timing of lum-
bar puncture may also of importance in interpreting
CSF findings. Moreover, the long conservation of CSF
samples in the tested collection as well as the conditions
of this conservation may also be responsible for the low
detection of LCN2 in true ABM cases. These consider-
ations may explain the relative low NPV (71%) in our
study. Under these conditions, the high likelihood ratio
of a positive result (11.6) indicates that a positive test
multiplies the pre-test odds by a factor of 11.6. This
means that the test is better at ruling in a condition than
ruling it out. This would be of interest in case the inci-
dence of acute bacterial meningitis is to be reduced after
the introduction of vaccines targeting agents of ABM.
The detection of lipocalin 2 in sera from infected mice
may allow discrimination when CSF was not collected or
lumber puncture was not feasible.
One limitation of our study is that the samples were
studied retrospectively and that the samples were enriched
for ABM (mainly meningococcal ABM) as there were sent
to the NRCM for suspicion of meningococcal meningitis.
The development of a rapid test (for example a dipstick
test) will open the possibility to perform a multisite study
with prospective inclusion of patients suffering of clinical
syndrome of meningitis. The performance of such a direct
and rapid test for LCN2 detection in CSF and blood will
be compared to that of other markers of ABM under the
conditions of “in routine” management of ABM.
Conclusion
Our data clearly indicate that LCN2 levels in CSF are
highly increased in CSF in patients with ABM. We suggest
that LCN2 detection in CSF from patients with clinical
meningitis may help in differential diagnosis between
acute bacterial and viral meningitis and may improve deci-
sion making for treatment algorithms in meningitis.
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